Breaking News Instant updates and real-time market news.

EXFO

EXFO Inc.

$4.05

0.025 (0.62%)

, ONCE

Spark Therapeutics

17:38
10/12/17
10/12
17:38
10/12/17
17:38

On The Fly: After Hours Movers

UP AFTER EARNINGS: EXFO (EXFO), up 12.4%. ALSO HIGHER: Spark Therapeutics (ONCE), up 6.5% after it confirmed that an FDA committee supports approval of LUXTURNA... Qiagen (QGEN), up 1.3% after it announced a bioinformatics collaboration with Centogene... Equifax (EFX), up 1.1% after CNBC reported that the company said its systems were not compromised in a recent reported issue. LOWER: Antares Pharma (ATRS), down 38.3% after it said that the FDA has identified deficiencies that preclude the continuation of the discussion of labeling and postmarketing requirements/commitments of XYOSTED at this time... Tandem Diabetes (TNDM), down 26.3% after it announced an offering of common stock and warrants... Applied Optoelectronics (AAOI), down 17.9% after its third quarter preliminary results missed consensus estimates... Endocyte (ECYT), down 8.9% after it filed to sell 5.28M shares of common stock for holders... AXT, Inc. (AXTI), down 4.9% after it said in a regulatory filing that COO Wilson Lin has resigned from the company... Patterson-UTI (PTEN), down 1.4% after it filed to sell 8.8M shares of common stock for holders.

EXFO

EXFO Inc.

$4.05

0.025 (0.62%)

ONCE

Spark Therapeutics

QGEN

QIAGEN

$34.17

-1.2 (-3.39%)

EFX

Equifax

$108.81

-1.69 (-1.53%)

ATRS

Antares Pharma

$3.73

-0.21 (-5.33%)

TNDM

TNDM

AAOI

Applied Optoelectronics

$58.84

-2.6 (-4.23%)

ECYT

Endocyte

$4.85

0.02 (0.41%)

AXTI

AXT, Inc.

$9.35

-0.05 (-0.53%)

PTEN

Patterson-UTI

$20.53

-0.78 (-3.66%)

  • 12

    Oct

  • 12

    Oct

  • 12

    Oct

  • 12

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 26

    Oct

  • 06

    Nov

  • 16

    Nov

  • 30

    Nov

  • 14

    Dec

  • 12

    Jan

  • 13

    Oct

EXFO EXFO Inc.
$4.05

0.025 (0.62%)

12/14/16
JPMS
12/14/16
NO CHANGE
Target $11
JPMS
Overweight
JPMorgan sees 88% upside for Viavi should it buy Ixia
JPMorgan analyst Rod Hall believes an acquisition of Ixia (XXIA) could drive shares of Viavi (VIAV) 88% higher due to deal accretion. Reuters on December 2 reported that Ixia is exploring options, including a possible sale. Ixia presents more upside potential for Viavi than other possible takeout candidates such as EXFO (EXFO), Hall tells investors in a research note. The analyst sees 34% upside for Viavi on a standalone basis and 51% upside from a takeover of EXFO. He continues to believe Viavi is likely to benefit from 3D sensing content in Apple's (AAPL) iPhone. Winning 3D sensing filters on the iPhone could result in more than $50M in incremental revenue for the company in 2017, Hall estimates. He keeps an Overweight rating on Viavi with an $11 price target.
ONCE Spark Therapeutics

10/12/17
RAJA
10/12/17
INITIATION
Target $96
RAJA
Outperform
Spark Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Spark Therapeutics (ONCE) with an Outperform and $96 price target given expectations for LUXTURNA approval in 2018, encouraging clinical data seen with the hemophilia A program, a top partner in Pfizer (PFE) driving development in hemophilia B, and a platform technology to address large areas of unmet need.
10/10/17
JEFF
10/10/17
NO CHANGE
JEFF
Buy
Spark Therapeutics briefing documents look positive, says Jefferies
Jefferies analyst Michael Yee believes the FDA advisory committee briefing document and questions posted ahead of a panel review of Spark Therapeutics' blindness gene therapy drug look "fairly benign and as expected," which he thinks the market will view as a positive. Yee, who thinks the panel is likely to vote in favor of FDA approval on Thursday, keeps a Buy rating on Spark Therapeutics, which is up fractionally in early trading at $86 per share.
10/06/17
GSCO
10/06/17
INITIATION
Target $111
GSCO
Buy
Spark Therapeutics resumed with a Buy at Goldman Sachs
Goldman analyst Salveen Richter resumed coverage on Spark Therapeutics with a Buy and $111 price target.
09/21/17
JEFF
09/21/17
NO CHANGE
Target $95
JEFF
Buy
Jefferies sees Spark rallying 5%-7% on positive FDA panel
Jefferies analyst Michael Yee sees a "high likelihood" for a positive FDA panel on October 12 for Spark Therapeutics' SPK-RPE65, setting up approval for the first gene therapy drug for rare blindness on or before the FDA action date of January 12, 2018. The analyst sees 5%-7% share upside on a positive vote, mostly as a "de-risking event and also a positive read-through derivative to gene therapy companies as FDA starts to approve gene therapy drugs." He keeps a Buy rating on Spark with a $95 price target.
QGEN QIAGEN
$34.17

-1.2 (-3.39%)

11/03/16
BOFA
11/03/16
UPGRADE
Target $26
BOFA
Neutral
QIAGEN upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded QIAGEN to Neutral and raised its price target to $26 from $25 following the Q3 report and solid FY17 guidance. The company sees accelerating FY17 growth and the first double-digit increase since 2012 and said its Unperform thesis is played out.
EFX Equifax
$108.81

-1.69 (-1.53%)

09/29/17
WBLR
09/29/17
NO CHANGE
WBLR
Outperform
William Blair, despite estimate cuts, positive on Equifax risk/reward
William Blair analyst Timothy McHugh lowered his estimates for Equifax to account for the data breach. The analyst cut his 2017 earnings per share estimate by 23c to $5.83, 2018 estimate by 83c to $5.91, and 2019 estimate by $1.05 to $6.35. Equifax will exclude some of the short-term items directly associated with the breach from its adjusted earnings, so the estimates do not include those items, McHugh tells investors in a research note. He now assumes organic growth for Equifax of 2% in 2018 and 6% in 2019. The analyst, while admitting the stock's multiple will not return to historical levels "anytime soon," views the company's risk/reward profile as "positive at current levels, particularly for patient investors." He keeps an Outperform rating on Equifax.
10/09/17
COWN
10/09/17
DOWNGRADE
Target $31
COWN
Underperform
Symantec downgraded to Underperform at Cowen
As reported previously, Cowen analyst Gregg Moskowitz downgraded Symantec (SYMC) to Underperform from Market Perform as he believes the recent spike in its price following the disclosure of the Equifax (EFX) breach is overdone. He also said its organic growth has been sluggish, its valuation is no longer cheap, and next-gen vendors are gaining traction. Moskowitz maintained his $31 price target on Symantec shares.
10/06/17
WELS
10/06/17
NO CHANGE
Target $127
WELS
Outperform
Wells Fargo reiterates Outperform on Equifax after Congressional testimony
Wells Fargo analyst William Warmington reiterates an Outperform rating on Equifax with a $127 price target following three days of Congressional testimony by former CEO Rick Smith. The legislative proposals discussed were either high-probability/low-impact, like requiring companies meet minimum cybersecurity standards and have a reaction plan in event of a breach,or low-probability/high-impact, like allowing consumers to opt out of having Equifax track their data and mandatory per-account fines for data breaches, Warmington tells investors in a research note. The analyst expects investor focus to shift to Equifax's preliminary 2018 guidance on its upcoming Q3 earnings call. He thinks the company's long-term growth model remains intact and introduced above-consensus 2019 revenue and earnings per shares estimates of $3.77B and $6.80. Many investors expect 2018 to be a "transition year" with revenue and costs impacted by the breach, Warmington writes.
10/03/17
JPMS
10/03/17
NO CHANGE
JPMS
Overweight
Political theatrics aside, JPMorgan expects reasonable credit bureau reform
Former Equifax CEO Rick Smith's testimony in front of Congress today will bring a fair amount of political theatrics, but ultimately, any regulatory changes for the credit bureau industry is likely to be "reasonable and manageable," JPMorgan analyst Andrew Steinerman tells investors in a research note. The analyst keeps an Overweight rating on shares of Equifax.
ATRS Antares Pharma
$3.73

-0.21 (-5.33%)

06/23/17
HCWC
06/23/17
INITIATION
Target $5
HCWC
Buy
Antares Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis initiated Antares Pharma with a Buy and a $5 price target saying he sees further upside as its diversified business strategy finally matures in the near future. The analyst said Antares is a sum-of-the-parts story, and we believe several of those parts could come into clarity within months, including potential 3Q17 A/B-rated generic EpiPen approval, Antares' own Xyosted testosterone PDUFA date, Oct. 2017, partnered generic Byetta approval/launch, and partnered Makena auto injector Oct. 2017 PDUFA. Davis expects cash flow to breakeven in second half 2018, profitability in 2019, and said sum-of-the parts valuation results in a $5 price target.
05/10/17
JEFF
05/10/17
NO CHANGE
Target $6
JEFF
Buy
Jefferies sees Antares shares getting to $15 over time
Jefferies analyst Anthony Petrone views Antares Pharma's Q1 report as "solid" ahead of a "catalyst rich" second half of 2017. The better than expected results reflect continued strength in Sumatriptan device sales to Teva (TEVA) and a rebound in Otrexup, Petrone tells investors in a post-earnings research note. He believes four new products can win clearance in the second half of the year. Petrone sees the stock getting to $15 over time on successful launches from current pipeline products and keeps a Buy rating on Antares with a $6 price target. The stock in afternoon trading is down 4% to $2.67.
04/20/17
RAJA
04/20/17
INITIATION
Target $4.3
RAJA
Strong Buy
Antares Pharma initiated with a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur initiated Antares Pharma with a Strong Buy and a $4.30 price target telling investors its business model diversity provides management with multiple value creation levers by playing in the generics arena targeting the $70B U.S. auto-injector and pre-filled syringe market, serving as life-cycle extension partner for branded assets facing end of life crisis or capturing full economic value of self-developed proprietary drugs.
03/31/17
JEFF
03/31/17
NO CHANGE
JEFF
Jefferies doubles Antares price target to $6 from $3
Jefferies analyst Anthony Petrone doubled this price target on shares of Antares Pharma to $6 from $3. The stock in early trading is up 7c to $2.81. In a research note today to investors, Petrone said his thesis on the company continues to be that its pipeline is well positioned to see a "succession of positive catalysts" over the next 24 months. Five pipeline products through 2019 collectively address $8B in new market opportunities, Petrone contends. He sees potential share upside to $15 with successful product launches "overtime." The FDA action date for Quickshot Testosterone, Antares' sub-Q testosterone replacement therapy, is October 20, 2017. Based on a "strong" clinical profile, the analyst assumes QST can capture 50% from existing brands or 15% of the total market.
TNDM TNDM

08/22/17
JPMS
08/22/17
NO CHANGE
JPMS
Overweight
Medtronic challenges in diabetes good news for Dexcom, Tandem, says JPMorgan
JPMorgan analyst Michael Weinstein noted that Medtronic (MDT) guided for its diabetes revenues to be down sequentially in the second and third quarters and lowered its diabetes growth guidance for the year. He said Medtronic's challenges "are naturally competitors' gains," and tells investors that he expects Dexcom (DXCM) and Tandem Diabetes (TNDM) to respond favorably to the news. Weinstein has an Overweight rating on Dexcom shares.
10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
J&J exit from insulin pumps a 'clear win' for Medtronic, says Piper Jaffray
After Animas, one of Johnson & Johnson's (JNJ) companies, announced that it intends to discontinue the manufacturing and sale of insulin pumps and selected Medtronic (MDT) as its transition partner, Piper Jaffray analyst Matt O'Brien called the news a "clear win" for Medtronic. For DexCom (DXCM), which has partnered with Animas, this decision is likely a modest negative, while Insulet (PODD) and Tandem (TNDM) may be able to capture some share from Animas pump patients who look for other therapeutic options, added O'Brien.
10/05/17
COWN
10/05/17
NO CHANGE
COWN
J&J exit 'great opportunity' for Insulet and Tandem, says Cowen
Cowen analyst Doug Schenkel says close to 10% of the U.S. insulin pump market is up for grabs over the next two years after Johnson & Johnson's (JNJ) Animas announced it is exiting the pump business. Medtronic (MDT) is likely to get the majority of patients initially, but the news is a "great opportunity" for Insulet (PODD) and Tandem Diabetes Care (TNDM), Schenkel tells investors in a research note. The analyst sees risk for Dexcom (DXCM), but believes the vast majority of its users will remain, regardless of pump choice.
10/10/17
WEDB
10/10/17
NO CHANGE
Target $17
WEDB
Outperform
Tandem Diabetes price target lowered to $17 from $50 at Wedbush
Wedbush analyst Tao Levy lowered his price target for Tandem Diabetes to $17 from $50 to reflect the risk of further dilution as it seeks to improve its cash position. He reiterates an Outperform rating on the shares.
AAOI Applied Optoelectronics
$58.84

-2.6 (-4.23%)

10/03/17
CHLM
10/03/17
NO CHANGE
Target $80
CHLM
Buy
Applied Optoelectronics price target lowered to $80 from $95 at Craig-Hallum
Craig-Hallum analyst Richard Shannon lowered his price target for Applied Optoelectronics (AAOI) to $80 from $95 on 40G transition acceleration and Intel (INTC) competitive threat. Nonetheless, the analyst says 100G+ remains robust, and Applied Optoelectronics' cost structure enables it to compete effectively. He reiterates a Buy rating on Applied Optoelectronics' shares.
10/02/17
BWSF
10/02/17
NO CHANGE
BWSF
Sell
BWS Financial sees Applied Optoelectronics sales to Amazon softening further
BWS Financial analyst Hamed Khorsand said he believes Applied Optoelectronics (AAOI) sales to Amazon (AMZN) have softened even more as the company moves away from 40G. He also thinks Intel's (INTC) start of shipments of a competing CWDM4 transceivers poses a threat to 100G revenue Applied has been generating from Facebook (FB). Khorsand keeps his Sell rating on Applied Optoelectronics shares.
08/24/17
NEED
08/24/17
NO CHANGE
NEED
China Mobile tender offer looks 'significant' for optical stocks, says Needham
Needham analyst Alex Henderson said the coherent transport ports tender offer announced by China Mobile (CHL) on its Chinese language website looks "significant in scale and material" for optical stocks. He noted that NeoPhotonics (NPTN) gets roughly 60% of revenue from China and is directly exposed to coherent demand, while Acacia (ACIA) gets 50% of revenue from China and is also directly exposed. He noted that Oclaro (OCLR), Lumentum (LITE), Finisar (FNSR) all have China exposure, but are less tied to coherent, while adding that "this order has no bearing" on Applied Optoelectronics (AAOI).
08/16/17
RAJA
08/16/17
NO CHANGE
RAJA
Strong Buy
Raymond James maintains Strong Buy rating on Applied Optoelectronics
Raymond James analyst Applied Simon Leopold maintained a Strong Buy and $107 price target on Applied Optoelectronics following a recent field trip. The analyst said Applied often gets grouped in with optical component stocks, but its differentiated through its focus on data center applications, scale and automation. Simon recommends investors take the time to listen to the story and further understanding will lead to increased appreciation.
ECYT Endocyte
$4.85

0.02 (0.41%)

06/05/17
COWN
06/05/17
DOWNGRADE
COWN
Market Perform
Endocyte downgraded to Market Perform at Cowen
As reported previously, Cowen analyst Boris Peaker downgraded Endocyte to Market Perform from Outperform due to the failure of its lead asset, EC1456, and higher uncertainty with its pipeline.
06/05/17
WEDB
06/05/17
DOWNGRADE
WEDB
Neutral
Endocyte downgraded on clinical data, pipeline changes at Wedbush
As noted earlier, Wedbush downgraded Endocyte to Neutral from Outperform. Analyst David Nierengarten downgraded the stock after the company reported that the level of activity observed in trials did not support further development of its EC1456 or its EC1169 in taxane-naive CRPC. The company will only develop EC1169 in the taxanes-exposed CRPC population going forward and will discontinue EC1456, the analyst reported. He removed all sales from both drugs from his model ,citing uncertain initial results of 1169 in the taxane-exposed population. Target to $2 from $8.
06/05/17
06/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Sector Weight from Overweight at Pacific Crest with analyst Andy Hargreaves saying upside from the launch of iPhone 8 is already reflected in the shares. An "extremely strong iPhone 8 cycle" is being priced into the stock while little weight is being given to gross margins, supply issues, or the likelihood for declines beyond the iPhone 8, Hargreaves tells investors in a research note. 2. Perrigo (PRGO) downgraded to Underperform from Sector Perform at RBC Capital with analyst Randall Stanicky saying the growth rate of the company's U.S. consumer business "has structurally re-rated lower" amid pricing headwinds and share losses. 3. Endocyte (ECYT) downgraded to Neutral from Outperform at Wedbush and to Market Perform from Outperform at Cowen. 4. Affiliated Managers (AMG) was downgraded to Neutral from Buy at Citi while Federated Investors (FII) was downgraded to Sell from Neutral. 5. Veeva (VEEV) downgraded to Equal Weight from Overweight at Morgan Stanley with the firm's analyst saying the 60%+ move in shares year-to-date captures much of the near-term upside in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/17
WEDB
10/03/17
UPGRADE
WEDB
Outperform
Endocyte upgraded to Outperform from Neutral at Wedbush
Wedbush analyst David Nierengarten upgraded Endocyte to Buy and increased its price target to $7 from $2 based on the attractive PSMA-617 opportunity and cheap valuation, despite share strength yesterday. The analyst sees potential peak sales of $1B and said it could have a broader opportunity and fewer hurdles in scaling up relative to Xofigo.
AXTI AXT, Inc.
$9.35

-0.05 (-0.53%)

03/17/17
RILY
03/17/17
DOWNGRADE
Target $7
RILY
Neutral
AXT, Inc. downgraded to Neutral from Buy at B. Riley
B. Riley analyst David Kang downgraded AXT, Inc. to Neutral and lowered his price target for the shares to $7 from $8.25 citing production uncertainty.
07/27/17
BWSF
07/27/17
NO CHANGE
Target $12
BWSF
Strong Buy
AXT, Inc. price target raised to $12 from $10 at BWS Financial
BWS Financial analyst Hamed Khorsand raised his price target for AXT, Inc. to $12 saying the company experienced growth in all substrate types in Q2. The analyst keeps a Buy rating on the shares.
04/11/17
BWSF
04/11/17
INITIATION
Target $10
BWSF
Buy
AXT, Inc. initiated with a Buy at BWS Financial
BWS Financial analyst Hamed Khorsand started AXT, Inc. with a Buy rating and $10 price target. Growing usage of high speed components in electronics is "creating a long product cycle with expanding profit margins," the analyst contends.
02/13/17
DOTC
02/13/17
INITIATION
Target $8
DOTC
Buy
AXT, Inc. initiated with a Buy at Dougherty
Dougherty analyst Joe Maxa initiated AXT, Inc with a Buy and an $8 price target.
PTEN Patterson-UTI
$20.53

-0.78 (-3.66%)

09/05/17
JPMS
09/05/17
UPGRADE
JPMS
Overweight
Patterson-UTI upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Sean Meakim upgraded Patterson-UTI to Overweight saying the 26% selloff since July 19 has created a buying opportunity. Despite having "solid exposure to the best volume and pricing story left in North America," frac, Patterson-UTI is the cheapest land driller under coverage, Meakim tells investors in a research note. The analyst keeps a $24 price target on the shares.
09/05/17
09/05/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying concerns over potential dilution from the BAMTech stake and the streaming apps are "widely overdone." 2. Patterson-UTI (PTEN) upgraded to Overweight from Neutral at JPMorgan with analyst Sean Meakim saying the 26% selloff since July 19 has created a buying opportunity. 3. lululemon (LULU) upgraded to Positive from Neutral at Susquehanna with analyst Sam Poser citing improved product mix, momentum carrying into the third quarter and inventory flow to stores that is finally supporting consumer engagement. 4. U.S. Steel (X) upgraded to Buy from Neutral at BofA/Merrill with analyst Timna Tanners saying the U.S. premium to Chinese prices has fallen to just about $75/ton, half the leves he considers "normal" and expects HRC can "surge toward $700/ton by year end. 5. Prologis (PLD) upgraded to Buy from Hold at SunTrust with analyst Ki Bin Kim citing valuation and several positive catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/17
DBAB
10/10/17
INITIATION
Target $25
DBAB
Buy
Patterson-UTI initiated with a Buy at Deutsche Bank
Deutsche Bank analyst David Havens started Patterson-UTI with a Buy rating and $25 price target.
08/31/17
SOCG
08/31/17
INITIATION
SOCG
Buy
Patterson-UTI initiated with a Buy at Societe Generale
Societe Generale analyst Edward Muztafago initiated Patterson-UTI with a Buy and a $22 price target due to large exposure to the US frac market. Muztafgo expects Patterson to benefit from a stronger backdrop for well completion activity combined with sunk drilling costs and a significant increase in drilled but uncompleted well backlog so far this year.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.